A ten-year budget impact simulation projected that integrating the PromarkerD biomarker test into routine type 2 diabetes care could delay kidney disease progression and reduce end-stage renal disease incidence. The analysis estimated net savings of $1.2 billion per one million patients and projected a 6.4% reduction in ESRD incidence. The modeling frames biomarker-guided screening as a payer-relevant intervention that changes downstream cost trajectories by identifying risk earlier and altering care intensity. The report adds another example of biomarker tests moving beyond clinical risk stratification into health-economic decision-making.
Get the Daily Brief